Ignite Creation Date:
2024-05-06 @ 6:18 PM
Last Modification Date:
2024-10-26 @ 2:45 PM
Study NCT ID:
NCT05619913
Status:
RECRUITING
Last Update Posted:
2024-02-08
First Post:
2022-10-26
Brief Title:
EPOCH Eribulin and Pembrolizumab in OvarianUterine Carcinosarcoma
Sponsor:
Australia New Zealand Gynaecological Oncology Group
Organization:
Australia New Zealand Gynaecological Oncology Group
Organization Data
Organization:
Australia New Zealand Gynaecological Oncology Group
Class:
OTHER
Study ID:
ANZGOG 18282021
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Australia New Zealand Gynaecological Oncology Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Eisai Inc | INDUSTRY |
| Merck Sharp Dohme LLC | INDUSTRY |